Levodopa/carbidopa bi-layer tablet - Impax Pharmaceuticals

Drug Profile

Levodopa/carbidopa bi-layer tablet - Impax Pharmaceuticals

Alternative Names: IPX-054

Latest Information Update: 12 Mar 2009

Price : $50

At a glance

  • Originator IMPAX Laboratories
  • Developer Impax Pharmaceuticals
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 19 Apr 2008 Efficacy data from a clinical trial in patients with Parkinson's disease presented at the 60th Annual Meeting of the American Academy of Neurology (AAN-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top